During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023.
Looking ahead in 2024, we are preparing for multiple data presentations for our six ongoing clinical programs. - Martin Welschof, CEO of
EVENTS IN THE FIRST QUARTER
Supply agreement signed with
EVENTS AFTER THE END OF THE PERIOD
New clinical trial collaboration and supply agreement signed with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA (pembrolizumab)
Regulatory event
FINANCIAL INFORMATION
First quarter 2024
Net sales,
Profit/loss after tax,
Profit/loss after tax per share before and after dilution,
Cash flow from operating activities,
Liquid funds, current and long-term investments at the end of the period,
About
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit.
Contact:
Tel: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
(C) 2024 Electronic News Publishing, source